Above: the company wordmark, photographed the way a record label might frame its logo - because that's roughly the metaphor. Clinical, genomic, imaging and claims data, all playing in time.
Picture an oncologist at the end of a long day. In front of her: one patient, one tumor, one decision. Behind her: tens of thousands of patients who came before, each with a record sitting in a system that does not talk to the next system. Their experience could inform this decision. It almost never does.
ConcertAI exists in that gap. The Cambridge, Massachusetts company takes the messy reality of cancer care - clinical notes, genomic tests, imaging scans, insurance claims - and turns it into something a researcher, or increasingly an algorithm, can actually learn from. It is not a hospital and not a drugmaker. It is the layer in between, the part that remembers what happened to everyone else.
The data already exists. The hard part was ever making it answer a question.
Clinical trials are how medicine learns, and they are gloriously, expensively slow. A trial can spend years just finding the right patients - the ones whose biology, history, and geography happen to line up with a protocol. Meanwhile the patients who were never in a trial generate evidence every single day, and most of it evaporates into incompatible databases.
The industry has a phrase for that wasted signal: real-world data. It sounds dull. It is not. If you could read it well enough, you could design better trials, match patients faster, and watch how treatments behave once they leave the controlled world of the study and enter the chaotic world of actual care.
Every patient who is not in a trial is still teaching us something. The question is whether anyone is listening.
The catch with real-world data: it is real, which is exactly why it is so wonderfully hard to use.
ConcertAI was founded in 2017 by Jeff Elton, who served as its founding CEO and is now Vice Chairman. The bet was specific: oncology, not all of medicine. Cancer is where the data is richest, the stakes are highest, and the molecular detail is deep enough that better evidence translates directly into better decisions.
The name is the thesis. A concert is many instruments playing in time under one conductor. ConcertAI's instruments are data types that normally refuse to share a stage - clinical, genomic, imaging, claims - and the conductor is AI. Get them in sync and you hear something no single source could play alone.
They did not try to fix all of healthcare. They picked the one disease where the data was worth the fight.
In 2025, the company handed the baton to a new conductor. Eron Kelly, formerly president of healthcare-SaaS firm Inovalon, became CEO to push ConcertAI deeper into generative and agentic AI, with Elton moving to Vice Chairman.
Underneath the brand is a platform called CARA - multi-modal data management with predictive and generative AI on top. Around it sits a set of products that each take a slice of the original problem and make it tractable.
The engine room: multi-modal data management plus predictive and generative AI that powers everything else.
One of the largest independent oncology data networks - clinical, molecular, claims, and imaging data, research-ready.
SaaS for clinical trial optimization, patient-to-trial matching, and eCRF automation. Less paperwork, faster enrollment.
AI-enhanced medical imaging across radiology, cardiology, and more - reaching roughly 1,300 clinical sites.
An oncology learning and research network, acquired from ASCO, extending reach into community practices.
Five products, one promise: turn what already happened into what should happen next.
The product is not the data and it is not the model. It is the moment they finally agree on an answer.
ConcertAI is founded in Cambridge, MA, by Jeff Elton with a focus on oncology real-world data.
Closes $150M in aggregate Series B financing to scale its data network.
Integrates TeraRecon, adding AI-enhanced medical imaging to the research network.
Raises a $150M Series C from Sixth Street at a reported ~$1.9B valuation.
Agrees to acquire CancerLinQ from ASCO to build a leading oncology learning network.
Expands BMS digital-trials partnership; announces NeoGenomics hematology RWD + generative AI collaboration.
Introduces new RWD-powered AI solutions at ASCO 2024.
Eron Kelly named CEO; founder Jeff Elton becomes Vice Chairman.
Vision is cheap in healthcare AI. Adoption is not. The case for ConcertAI rests on who runs on it and how much money has been wagered on it being right.
Bars are scaled for visual comparison, not a single shared unit - dollars, people, and sites do not share an axis, much like the data ConcertAI exists to reconcile.
The customer list reads like an oncology who's-who. Bristol Myers Squibb expanded its digital-trials partnership for faster enrollment. NeoGenomics teamed up on population-scale hematology data. Caris Life Sciences joined on molecular research. ASCO trusted the company enough to hand over CancerLinQ.
You can argue with a vision. It is harder to argue with the names willing to put their patients' data behind it.
ConcertAI describes its purpose plainly: accelerate insights and outcomes for patients through research-ready data, CARA AI technologies, and scientific expertise, working alongside biomedical innovators, providers, and medical societies. Stripped of jargon, the mission is to make sure the patient who came before is not forgotten when the next decision is made.
It is a B2B company - it sells software subscriptions, data access, and scientific services - but the end customer is a person in a clinic who never sees the logo. That distance between business model and beneficiary is the honest tension of the whole sector. ConcertAI's bet is that better evidence, sold to the right institutions, eventually reaches the bedside.
The mission is not to build the smartest model. It is to make sure the last patient's experience reaches the next one.
The next frontier the company is chasing is agentic AI - systems that do not just surface evidence but act on it, threading through trial design, patient matching, and decision support. New CEO Eron Kelly's mandate is to push there faster. Skeptics will note that healthcare is where bold AI promises go to meet regulation, privacy, and the stubborn messiness of real clinical life. Fair. The graveyard of health-tech is full of confident slogans.
But return to where we started. That oncologist at the end of her day, one patient in front of her and tens of thousands behind. The whole point of ConcertAI is that the people behind her are no longer silent. Their records have been cleaned, connected, and read. When she reaches for the next decision, the evidence of everyone who came before is finally in the room with her.
That is the change the company is trying to make: not a louder algorithm, but a quieter clinic where nothing useful gets lost. The orchestra is still tuning. But for the first time, the room can hear it.
She still makes the call. She just no longer makes it alone.